At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 148 enrolled
Drug / intervention
Olaratumab +1 morebiological
Likely dose
Olaratumab 15 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2, With Phase 2 Randomized, Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
In Brief
A Phase 2 clinical trial evaluating Olaratumab and doxorubicin for Sarcoma, Soft Tissue. Completed, enrolled 148 participants across 17 sites.
Detailed Summary
The main purpose of this study is to gather information about the use of an investigational drug called olaratumab with a drug for soft tissue sarcoma called doxorubicin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma, Soft Tissue
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartOct 2010
Primary CompletionAug 2014
Study CompletionApr 2016
TodayJul 2026
First PostedAug 20, 2010
Enrollment StartOct 1, 2010
Primary CompletionAug 1, 2014
Study CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 15.9 years ago
Interventions
Olaratumabbiological
Olaratumab 15 mg/kg by intravenous transfusion (I.V.) on days 1+8 of a 21-day cycle
doxorubicindrug
Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.